⁶⁸Ga-FAPI as a Diagnostic Tool in Sarcoma: Data from the ⁶⁸Ga-FAPI PET Prospective Observational Trial.

ABSTRACT: Bone and soft-tissue sarcomas express fibroblast activation protein (FAP) on tumor cells and associated fibroblasts. Therefore, FAP is a promising therapeutic and diagnostic target. Novel radiolabeled FAP inhibitors (e.g., ⁶⁸Ga-FAPI-46) have shown high tumor uptake on PET in sarcoma patients. Here, we report the endpoints of the ⁶⁸Ga-FAPI PET prospective observational trial. Methods: Forty-seven patients with bone or soft-tissue sarcomas undergoing clinical ⁶⁸Ga-FAPI PET were eligible for enrollment into the ⁶⁸Ga-FAPI PET observational trial. Of these patients, 43 also underwent ¹⁸F-FDG PET. The primary study endpoint was the association between ⁶⁸Ga-FAPI PET uptake intensity and histopathologic FAP expression analyze

SUBMITTER: Kessler L 

PROVIDER: S-EPMC8717183 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature